Trial Profile
A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Izokibep (Primary) ; Izokibep (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 16 Jul 2019 Results published in Affibody Media Release.
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Nov 2017 Planned number of patients changed from 64 to 76.